BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:vunakizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of vunakizumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06779097-111@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:vunakizumab: Phase 4 readout est. (NCT06779097)
DESCRIPTION:vunakizumab\, phase 4\, Psoriasis.\nStudy: Phase IV Study: Vuna
 kizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis\nEstima
 ted primary completion: March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/vunakizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06779097
URL:https://assetmemo.bio/drug/vunakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07373847-111@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:vunakizumab: Phase 4 readout est. (NCT07373847)
DESCRIPTION:vunakizumab\, phase 4\, Psoriasis.\nStudy: Vunakizumab Combined
  With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and
  Dyslipidemia\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/vunakizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07373847
URL:https://assetmemo.bio/drug/vunakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860750-111@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:vunakizumab: Phase 3 readout est. (NCT06860750)
DESCRIPTION:vunakizumab\, phase 3.\nStudy: A Trial of SHR-1314 Injection in
  Adult Patients With Active Non-radiographic Axial Spondyloarthritis\nEsti
 mated primary completion: February 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/vunakizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06860750
URL:https://assetmemo.bio/drug/vunakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
